Rani Therapeutics Holdings, Inc. Class A Share Price
RANIRani Therapeutics Holdings, Inc. Class A Stock Performance
Open $1.93 | Prev. Close $2.00 | Circuit Range N/A |
Day Range $1.89 - $2.13 | Year Range $0.39 - $3.85 | Volume 83,297 |
Average Traded $1.95 |
Rani Therapeutics Holdings, Inc. Class A Share Price Chart
About Rani Therapeutics Holdings, Inc. Class A
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Rani Therapeutics Holdings, Inc. Class A Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
12-Nov-25 | $1.93 | $2.10 | +0.00% |
12-Nov-25 | $1.93 | $2.10 | +9.35% |
11-Nov-25 | $1.93 | $1.93 | +2.67% |
10-Nov-25 | $2.08 | $1.88 | -6.95% |
07-Nov-25 | $1.93 | $2.02 | -10.24% |
06-Nov-25 | $2.49 | $2.25 | -10.20% |
05-Nov-25 | $2.42 | $2.50 | +5.49% |